|
|||||
|
|
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients |
|
| Authors: | J. TEITEL E. BERNTORP G. DOLAN K. FISCHER A. GRINGERI C. KESSLER T. LAMBERT C. LEISSINGER L. NEMES M. SHIMA |
| Affiliation: | 1. St Michael’s Hospital Department of Medicine and the University of Toronto, Toronto, ON, Canada;2. Lund University, Malm? Centre for Thrombosis and Haemostasis, Malm?, Sweden;3. Nottingham University Hospitals, Queens Medical Center, Nottingham, UK;4. van Creveldkliniek, Utrecht, The Netherlands;5. A. Bianchi Bonomi Haemophilia and Thrombosis Center, University of Milan, Milan, Italy;6. Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA;7. H?pital de Bicêtre AP‐HP, Paris, France;8. Louisiana Center for Bleeding and Clotting, Tulane University Medical Center, New Orleans, LA, USA;9. State Health Center, Budapest, Hungary;10. Department of Pediatrics, Nara Medical University, Kashihara, Japan |
| Abstract: | Summary. The haemophilia literature increasingly contains reports describing the use of bypassing agent prophylaxis (BAP) in patients with severe haemophilia A and inhibitors. However, it is difficult to interpret and compare the results and draw conclusions about treatment efficacy because of small patient numbers and a lack of standardization among BAP studies. This article presents consensus recommendations for standardizing future BAP clinical trials developed by an international panel of haemophilia opinion leaders. |
| Keywords: | activated prothrombin complex concentrate activated recombinant factor VII bypassing therapy haemophilia inhibitors prophylaxis |